Recursion Pharmaceuticals, Inc. (RXRX) 25th Annual Needham Virtual Healthcare Conference April 13, 2026 12:45 PM EDTCompany ParticipantsBen Taylor - ...

In the spring of 2020, the digital world served as our global lighthouse, providing orientation and connection when the ...

Generic formats like JSON or XML are easier to version than forms. However, they were not originally intended to be ...

Holding signs and banners reading Stop the AI Race and Don’t Build Skynet, the protesters marched through the city and gave speeches outside the offices of Anthropic, OpenAI, and xAI. The crowd ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Add a description, image, and links to the recursion-and-dynamic-programming topic page so that developers can more easily learn about it.

Chris Gibson, the CEO of Recursion Pharmaceuticals, thinks the future of drug discovery lies within a ChatGPT-like interface. At a J.P. Morgan Healthcare Conference reception co-hosted with Nvidia, ...